Paul S. Aisen

Paul S. Aisen's AcademicInfluence.com Rankings

Paul S. Aisen

Philosophy

#4481

World Rank

#7013

Historical Rank

Logic

#1920

World Rank

#2792

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Paul S. Aisen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paul S. Aisen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (5616)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) (3896)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers (2013) (3207)
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. (2012) (2815)
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) (1922)
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. (2014) (1327)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (2003) (920)
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. (2004) (917)
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. (2013) (906)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010) (712)
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. (2010) (704)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (624)
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. (2000) (594)
The A4 Study: Stopping AD Before Symptoms Begin? (2014) (593)
Comparing predictors of conversion and decline in mild cognitive impairment (2010) (570)
The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception (2012) (553)
Amyloid deposition, hypometabolism, and longitudinal cognitive decline (2012) (534)
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2012) (513)
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. (2008) (506)
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. (2014) (491)
Testing the Right Target and Right Drug at the Right Stage (2011) (485)
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) (473)
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study (2008) (469)
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease (2010) (464)
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain (1998) (444)
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease (2011) (434)
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease (2015) (434)
Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease (2018) (411)
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease (2017) (397)
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans (2010) (395)
Symptom onset in autosomal dominant Alzheimer disease (2014) (338)
Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease (2019) (330)
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. (2012) (328)
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. (2008) (325)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Inflammatory mechanisms in Alzheimer's disease: implications for therapy. (1994) (311)
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects (2010) (311)
Drug development in Alzheimer’s disease: the path to 2025 (2016) (295)
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons (2017) (289)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2015) (287)
On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (269)
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease (2011) (263)
Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. (1989) (257)
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease (2012) (248)
Regional distribution of cyclooxygenase‐2 in the hippocampal formation in Alzheimer's disease (1999) (246)
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model (2008) (241)
A randomized controlled trial of prednisone in Alzheimer’s disease (2000) (240)
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. (2000) (230)
Mild cognitive impairment due to Alzheimer disease in the community (2013) (228)
Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) (2011) (226)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative (2018) (225)
Evidence for ordering of Alzheimer disease biomarkers. (2011) (217)
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials (2017) (214)
Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions (2015) (211)
A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease (2008) (210)
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement (2017) (206)
Recent developments in Alzheimer's disease therapeutics (2009) (195)
A phase II trial of huperzine A in mild to moderate Alzheimer disease (2011) (193)
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. (2001) (191)
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease (2006) (189)
Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. (2000) (189)
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease (2002) (189)
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. (2012) (186)
APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study (2013) (184)
Maturational Regulation and Regional Induction of Cyclooxygenase-2 in Rat Brain: Implications for Alzheimer's Disease (1997) (184)
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials (2019) (180)
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. (2011) (175)
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI (2011) (175)
Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort (2010) (175)
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 (2015) (175)
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment (2008) (173)
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease (2009) (169)
Longitudinal change of biomarkers in cognitive decline. (2011) (169)
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage (2007) (164)
Report of the task force on designing clinical trials in early (predementia) AD (2010) (162)
Randomized pilot study of nimesulide treatment in Alzheimer’s disease (2002) (161)
Biological markers of amyloid β-related mechanisms in Alzheimer's disease (2010) (157)
Serial MRI and CSF biomarkers in normal aging, MCI, and AD (2010) (151)
Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome (2009) (150)
Estimating long-term multivariate progression from short-term data (2014) (147)
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease (2014) (142)
Complement‐derived anaphylatoxin C5a protects against glutamate‐mediated neurotoxicity (1999) (140)
Biomarkers for Alzheimer's disease therapeutic trials (2011) (138)
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern (2015) (138)
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) (2013) (137)
Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force (2013) (137)
PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease (2011) (134)
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. (2016) (133)
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). (2006) (133)
Chronic divalproex sodium use and brain atrophy in Alzheimer disease (2011) (132)
Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. (1997) (132)
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. (2020) (129)
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. (2012) (129)
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. (2013) (127)
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. (2012) (126)
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. (2015) (125)
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. (2020) (125)
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. (2019) (125)
Effect of tramiprosate in patients with mild-to-moderate alzheimer’s disease: Exploratory analyses of the MRI sub-group of the alphase study (2009) (118)
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition (2011) (116)
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease (2022) (116)
A phase 3 trial of IV immunoglobulin for Alzheimer disease (2017) (115)
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering (2021) (114)
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β (2017) (114)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
Alzhemed: a potential treatment for Alzheimer's disease. (2007) (113)
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial (2018) (113)
Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial (2018) (113)
Incidence of new-onset seizures in mild to moderate Alzheimer disease. (2012) (112)
Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau (2011) (110)
Update on hypothetical model of Alzheimer's disease biomarkers (2013) (109)
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. (2015) (108)
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. (2014) (108)
Nicotine treatment of mild cognitive impairment (2012) (108)
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique (2001) (103)
Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s Disease neuropathology (2002) (103)
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice 2 (2006) (101)
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study (2010) (101)
The Development of Anti-Amyloid Therapy for Alzheimer’s Disease (2005) (97)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
CSF biomarker and PIB-PET–derived beta-amyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects (2011) (95)
The search for disease-modifying treatment for Alzheimer's disease (1997) (93)
Advances in Alzheimer’s Disease Drug Development (2015) (92)
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid (2011) (92)
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression (2018) (92)
Plasma Urate and Progression of Mild Cognitive Impairment (2008) (90)
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease (2014) (90)
Association between tau deposition and antecedent amyloid-&bgr; accumulation rates in normal and early symptomatic individuals (2017) (88)
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI (2010) (87)
Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. (2004) (86)
CAP—advancing the evaluation of preclinical Alzheimer disease treatments (2016) (85)
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects (2010) (85)
Nonlinear time course of brain volume loss in cognitively normal and impaired elders (2012) (81)
Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment (2013) (76)
Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. (2012) (76)
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease (2019) (75)
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. (2012) (75)
Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease (2015) (74)
Inflammation and Alzheimer disease (1996) (74)
The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans (2015) (72)
The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome (2015) (71)
Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future (2015) (71)
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials (2018) (71)
Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks (2012) (67)
A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. (2003) (67)
Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death (1998) (67)
Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. (2002) (66)
A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice (2011) (66)
Alzheimer’s Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans (2015) (66)
Prevention trials in Alzheimer's disease: An EU-US task force report (2011) (65)
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease (2013) (65)
Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. (2014) (65)
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. (2014) (64)
ADCS Prevention Instrument Project: Overview and Initial Results (2006) (64)
Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment (2010) (63)
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. (2014) (63)
ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI) (2006) (63)
Anti-inflammatory therapy in Alzheimer’s disease: is hope still alive? (2003) (62)
The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding (2015) (62)
Dependence as a unifying construct in defining Alzheimer's disease severity (2010) (62)
Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report (2017) (60)
Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. (2016) (60)
Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease (2017) (60)
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. (2005) (59)
Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease (2012) (59)
Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease (2017) (58)
Health‐Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment (2013) (58)
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease (2016) (57)
Protective variant for hippocampal atrophy identified by whole exome sequencing (2015) (56)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Alzheimer's disease therapeutic research: the path forward (2009) (56)
An update on huperzine A as a treatment for Alzheimer's disease (2008) (56)
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative (2014) (55)
Can lithium or valproate untie tangles in Alzheimer's disease? (2009) (54)
Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel (2013) (54)
Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild Cognitive Impairment But Not Alzheimer Disease (2011) (52)
Effect of study partner on the conduct of Alzheimer disease clinical trials (2013) (52)
Down's syndrome and Alzheimer's disease: towards secondary prevention (2012) (51)
Focal hemosiderin deposits and β-amyloid load in the ADNI cohort (2013) (51)
A pilot study of prednisone in Alzheimer's disease. (1996) (50)
Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. (2016) (50)
A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology (2016) (49)
Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention (2020) (48)
The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. (2016) (48)
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study (2014) (48)
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years (2015) (47)
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. (2015) (47)
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 (2010) (45)
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease (2015) (45)
Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease (2010) (45)
Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology (2012) (45)
Methodological issues in primary prevention trials for neurodegenerative dementia. (2009) (44)
Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force (2019) (44)
The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline (2014) (44)
The transitional association between β-amyloid pathology and regional brain atrophy (2014) (44)
Circulating hydroxy fatty acids in familial Mediterranean fever. (1985) (44)
IL-1 and anti-inflammatory drugs modulate A β cytotoxicity in PC12 cells (1996) (44)
Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. (2015) (43)
Vitamin E in aging persons with Down syndrome (2016) (42)
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report (2019) (42)
Brain structure and function as mediators of the effects of amyloid on memory (2015) (41)
Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. (2016) (41)
Elevated CSF prostaglandin E2 levels in patients with probable AD. (2000) (41)
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). (2015) (40)
Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study (2019) (38)
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status (2014) (38)
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. (2021) (38)
Glucocorticoids in Alzheimer’s Disease (1998) (38)
Serial MRI and CSF biomarkers in normal aging, MCI and Alzheimer's disease (2010) (38)
The Future of Anti-Amyloid Trials (2019) (37)
Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease (2017) (36)
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience (2009) (35)
Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment (2011) (35)
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. (2008) (35)
The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. (2012) (34)
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease (2015) (34)
Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. (2001) (34)
Hypochondriasis in the Elderly Depressed (1989) (34)
Anti‐inflammatory therapy for Alzheimer's disease: implications of the prednisone trial (2000) (34)
Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. (2015) (33)
FASTKD2 is associated with memory and hippocampal structure in older adults (2014) (33)
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. (2013) (33)
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease (2019) (33)
Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010 (2011) (32)
Neuropsychiatric Symptoms and Regional Neocortical Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease (2014) (32)
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease (2020) (31)
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. (2020) (31)
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. (2020) (31)
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (30)
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment (2015) (30)
Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease (2015) (30)
Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. (2020) (30)
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2 (2002) (29)
Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment (2016) (29)
Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years (2011) (29)
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. (2017) (28)
The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. (2017) (28)
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
Early Indications of Future Cognitive Decline: Stable versus Declining Controls (2013) (28)
Elevated Plasma Neopterin Levels in Alzheimer Disease (2000) (27)
Predicting the course of Alzheimer’s progression (2019) (27)
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention (2019) (27)
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers (2021) (27)
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials (2015) (27)
Focal hemosiderin deposits and beta-amyloid load in the ADNI cohort (2013) (27)
Alzheimer’s disease progression by geographical region in a clinical trial setting (2015) (27)
Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials (2016) (27)
Unsuccessful trials of therapies for Alzheimer's disease (2019) (27)
Impact of apolipoprotein ɛ4–cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment (2011) (27)
Inflammatory processes and Alzheimer’s disease (2004) (26)
Deglycosylated anti‐amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration (2007) (26)
Familial hyperoxaluria. Report of a family, review of the literature. (1960) (24)
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease (2017) (24)
The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome (2009) (24)
Falls among geropsychiatry inpatients are associated with prn medications for agitation (1992) (24)
Passive immunotherapy for Alzheimer’s disease: What have we learned, and where are we headed? (2013) (23)
Pilot Tolerability Studies of Hydroxychloroquine and Colchicine in Alzheimer Disease (2001) (23)
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease (2021) (23)
Requiring an amyloid-β1–42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials (2011) (23)
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease (2016) (22)
Falls on a neurorehabilitation unit: reassessment of a prevention program. (1994) (22)
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease (2021) (22)
The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial (2020) (22)
Assessment of Aging Individuals with Down Syndrome in Clinical Trials: Results of Baseline Measures (2005) (22)
The effects of nucleosides on the resistance of normal human erythrocytes to osmotic lysis. (1957) (22)
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. (2017) (22)
SELEGILINE IN THE TREATMENT OF BEHAVIOURAL DISTURBANCE IN ALZHEIMER'S DISEASE (1997) (22)
Treatment for MCI (2008) (21)
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition (2011) (21)
Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study (2013) (21)
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials (2015) (21)
Randomized controlled trials in mild cognitive impairment (2017) (21)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Generation of C5-derived peptides and other immune reactants in the sera of patients with systemic lupus erythematosus. (1984) (21)
The net effect of alternative allocation ratios on recruitment time and trial cost (2009) (21)
Failure After Failure. What Next in AD Drug Development? (2019) (20)
Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. (1998) (20)
Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia (2010) (20)
Serum brain-derived neurotrophic factor and the risk for dementia. (2014) (20)
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials (2020) (20)
Anti-inflammatory agents in Alzheimer’s disease (2002) (20)
The ADCS valproate neuroprotection trial: Primary efficacy and safety results (2009) (20)
NSAIDs and hypertension (2003) (20)
In vivo protein transduction to the CNS (2006) (19)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
Mixed model of repeated measures versus slope models in Alzheimer’s disease clinical trials (2012) (18)
Clinical trial methodologies for disease-modifying therapeutic approaches (2011) (18)
Apolipoprotein E ε4 Does Not Modulate Amyloid-β–Associated Neurodegeneration in Preclinical Alzheimer Disease (2013) (18)
Early-stage Alzheimer disease: getting trial-ready (2022) (18)
A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. (2011) (18)
The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview (2020) (18)
Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. (2008) (17)
Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. (2018) (17)
Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease (2009) (17)
THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY (2014) (17)
Tarenflurbil: a shot on goal (2008) (17)
Developing Dementia Prevention Trials: Baseline Report of the Home-Based Assessment Study (2013) (17)
Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative (2018) (17)
Antibody against C-terminal Abeta selectively elevates plasma Abeta (2007) (17)
A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease (2009) (16)
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology (2021) (16)
A Pilot Study of Oral Physostigmine Plus Yohimbine in Patients with Alzheimer Disease (1993) (16)
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease (2021) (16)
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials (2011) (16)
Cross-validation of optimized composites for preclinical Alzheimer's disease (2016) (16)
Erratum to “Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial” [Rev. Neurol. 169 (10) (2013) 737–743] (2013) (16)
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management (2021) (16)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
Trazodone for Behavioral Disturbance in Alzheimer's Disease. (1993) (15)
Estimating the Evolution of Disease in the Parkinson’s Progression Markers Initiative (2018) (15)
Benchmarking a Test of Temporal Orientation with Data from American and Taiwanese Persons with Alzheimer’s Disease and American Normal Elderly (2004) (14)
Right lateral prefrontal cortex—specificity for inhibition or strategy use? (2015) (14)
Pre-dementia Alzheimer's trials: overview. (2010) (14)
Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo (2009) (14)
HLA-DR4 influences glial activity in Alzheimer's disease hippocampus (1998) (14)
Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. (2016) (14)
Phase 2 Safety Trial Targeting Amyloid (cid:1) Production With a (cid:2) -Secretase Inhibitor in Alzheimer Disease (2008) (14)
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD) (2020) (14)
Anti-inflammatory therapy for Alzheimer’s disease (2000) (14)
Independent contributions of neural and “higher-order” deficits to symptoms in Alzheimer’s disease: A latent variable modeling approach (2006) (13)
The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease (2022) (13)
Statistical properties of continuous composite scales and implications for drug development (2017) (13)
Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial (2021) (13)
Shoulder-hand syndrome in cervical spinal cord injury (1994) (13)
Steroid-induced elevation of glucose in Alzheimer’s disease: relationship to gender, apolipoprotein E genotype and cognition (2003) (13)
Using the Guttman Scale to Define and Estimate Measurement Error in Items over Time: The Case of Cognitive Decline and the Meaning of “Points Lost” (2012) (13)
Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force (2018) (13)
Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (2019) (13)
Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials (2016) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo (2008) (12)
Considerations in the design of clinical trials for cognitive aging. (2012) (12)
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force (2021) (12)
A pilot study of clonidine plus physostigmine in Alzheimer's disease. (1994) (12)
A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease (2018) (12)
Glucocorticoids in Alzheimer's disease. The story so far. (1998) (11)
Determinants of Length of Stay in Geropsychiatry. (1994) (11)
One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline (2005) (11)
Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability (2018) (11)
TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology (2020) (11)
The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years (2020) (11)
Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? (2018) (10)
The inflammatory hypothesis of Alzheimer disease: dead or alive? (2008) (10)
Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics (2013) (10)
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report (2020) (10)
Therapeutics for cognitive aging (2010) (10)
The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease (2019) (10)
THE A4 TRIAL: ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE (2012) (10)
Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial (2018) (10)
Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer’s Disease (2019) (10)
COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE (2014) (10)
Dr. Doody and colleagues reply (2014) (10)
Interpreting biomarker data in therapeutic trials (2009) (10)
Cognitive/Clinical Endpoints for Pre-Dementia AD Trials. (2015) (10)
An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents (2005) (9)
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data (2021) (9)
A simple method to rule out dementia with temporal orientation (2007) (9)
Semagacestat for treatment of Alzheimer's disease. (2013) (9)
for the Treatment of Alzheimer's Disease (2002) (9)
New Hope for Alzheimer’s Disease (2021) (9)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease (2022) (9)
The search for Alzheimer disease therapeutics — same targets, better trials? (2020) (9)
Pulmonary embolism presenting as fever in spinal cord injury patients: report of two cases and review of the literature. (1993) (9)
Early Alzheimer’s trials: New developments (2010) (8)
The sympathetic skin response in the shoulder-hand syndrome complicating tetraplegia (1995) (8)
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study (2021) (8)
AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial) (2020) (8)
Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia. (2016) (8)
Commentary on “Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials” (2006) (8)
What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force (2018) (8)
Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease (2015) (8)
Agreement in Cognitive and Clinical Assessments in Alzheimer’s Disease (2009) (8)
What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty (2010) (7)
Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid (2003) (7)
Design and implementation of a multicenter trial of vitamin E in aging individuals with Down syndrome (2005) (7)
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study (2020) (7)
Blood Pressure Lowering With Nilvadipine in Patients With Mild‐to‐Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension (2019) (7)
Q & A: The Alzheimer's disease neuroimaging initiative (2011) (7)
Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease (2017) (7)
Shapes of the Trajectories of Five Major Biomarkers of Alzheimer’s Disease (2013) (7)
Increased levels of tau-like protein in patients with Down syndrome (1999) (7)
Development of antiinflammatory therapy for Alzheimer's disease (2002) (7)
Physics and physiology of transferrin. (1970) (7)
Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults (2019) (7)
Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) (2016) (6)
Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. (2022) (6)
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force (2021) (6)
Pre-dementia Alzheimer’s trials: Overview (2010) (6)
Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018 (2019) (6)
IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. (1996) (6)
How Will Aducanumab Approval Impact AD Research? (2021) (6)
Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001) (2019) (6)
Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business (2020) (6)
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4 (2022) (6)
Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 (2018) (6)
GPSYCH: Clinical management software for a Geropsychiatry Division. (1992) (5)
Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach (2020) (5)
Transforming CSF A β 42 measures into calculated Pittsburgh Compound B ( PIBcalc ) units of brain A β amyloid (2011) (5)
Individuals with Alzheimer's disease exhibit a high prevalence of undiagnosed impaired glucose tolerance and type 2 diabetes mellitus (2013) (5)
Phase II safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer's disease (2009) (5)
P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study (2008) (5)
An Abeta sequestration approach using non-antibody Abeta binding agents. (2005) (5)
EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. (2014) (5)
The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. (2021) (5)
Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism. (2017) (5)
Neuroleptic malignant syndrome induced by low-dose haloperidol. (1992) (5)
On the path to 2025: understanding the Alzheimer’s disease continuum (2017) (4)
Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease (2008) (4)
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program (2021) (4)
Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2 (2021) (4)
Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. (2014) (4)
Ordering of Alzheimer's disease biomarkers (2011) (4)
MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials: Baseline Comparability of a Substudy Sample to Entire Study Population (2009) (4)
Alzheimer disease cooperative study (ADCS) home based assessment: Designing trials with new technology (2011) (4)
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2022) (4)
A randomized clinical trial to evaluate home-based assessment of people over 75 years old (2019) (4)
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Facilitating Alzheimer's disease drug development in the United States (2009) (4)
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke (2008) (4)
Systemic lupus erythematosus in a patient with Reiter's syndrome. (1983) (4)
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. (2005) (4)
Commentary on “The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006.”—An appraisal (2007) (4)
Detecting When “Quality of Life” Has Been “Enhanced”: Estimating Change in Quality of Life Ratings (2013) (4)
Expectations and clinical meaningfulness of randomized controlled trials. (2023) (4)
Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer’s Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls (2020) (4)
P2-321 How much do 12 month changes in cognition and function influence changes in mild to moderate AD patients and caregivers ratings of patient quality of life? (2004) (4)
APOE effect on Alzheimer’s biomarkers in older adults with significant memory concern (2015) (3)
Acceleration of brain atrophy rates with advancing cognitive deterioration from normal aging to MCI to Alzheimer's disease (2011) (3)
Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers (2022) (3)
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies (2021) (3)
What We Learn from the CTAD 2018 (Clinical Trials Alzheimer’s Disease) (2018) (3)
Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? (2005) (3)
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials (2022) (3)
S3-02-01 ADCS homocysteine trial (2007) (3)
Resveratrol is safe and well-tolerated in individuals with mild-moderate dementia due to Alzheimer’s disease. (S33.009) (2015) (3)
Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI (2022) (3)
ACCEPTABILITY, USABILITY, VALIDITY AND SENSITIVITY OF COGNITION ASSESSED IN UNSUPERVISED SETTINGS (2017) (3)
ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trails (2022) (3)
Antidepressant use and orthostatic hypotension in older adults living with mild‐to‐moderate Alzheimer disease (2020) (3)
TAU PET IN A4: PRELIMINARY REPORT (2018) (3)
Transforming CSF Aβ42 measures of brain beta-amyloid into calculated PIB (PIBcalc) units (2010) (3)
Functional GAG mimetics as an approach for the treatment of amyloid diseases (2005) (3)
Data-Driven Participant Recruitment: Findings from the Alzheimer’s Disease Neuroimaging Initiative 3 (2020) (3)
Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trials (2022) (3)
THE ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS (2018) (3)
Low Retention of [S-methyl-11C]MeS-IMPY to β-amyloid Plaques in Patients with Alzheimers Disease (2009) (3)
Impact of apolipoprotein varepsilon4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment (2011) (3)
Antinuclear antibodies in multiple sclerosis (1995) (2)
Medical cost containment: a daily patient log sheet to reduce unnecessary hospitalization. (1987) (2)
NAP ameliorates Alzheimer’s pathology in ad model mouse (2006) (2)
Development of a disease-modifying treatment for Alzheimer’s disease: Alzhemed (2006) (2)
Self- versus informant-based cognitive complaints: Relation of E-Cog scores to imaging, biomarkers and clinical Status in ADNI-2 (2013) (2)
TRC-PAD: USING RUN-IN DATA FOR SCREEN FAILURE REDUCTION (2016) (2)
An aspirin a day for Alzheimer's disease? (2008) (2)
The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results (2012) (2)
Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. (2020) (2)
3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI (2010) (2)
Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (2)
P3-040: Alzheimer's disease neuroimaging initiative: Baseline characteristics (2008) (2)
OPEN LABEL EXTENSION RESULTS FROM A PHASE II/III TRIAL OF INTRANASAL INSULIN (2019) (2)
Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease (2016) (2)
Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center (2010) (2)
ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC AD: A4 AND BEYOND (2016) (2)
Sex‐associated differences in pathology burden in early‐onset Alzheimer’s disease (2020) (2)
Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials (2012) (2)
O4-04-03: A neuronal microtubule-interacting agent, nap, reduces hyperphosphorylated Tau and insoluble Tau, and enhances cognitive function in a transgenic mouse model of Alzheimer's disease (2008) (2)
Alzheimer’s prevention registry: A shared resource to the scientific community to facilitate enrollment in studies (2015) (2)
Neither rofecoxib nor naproxen slows cognitive decline in people with mild-to-moderate Alzheimer's disease (2003) (2)
Satisfaction of elderly research volunteers with home-based clinical trial participation (2013) (2)
MACHINE LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER’S DISEASE (2017) (2)
Elevated Brain Amyloid in Cognitively Normal Individuals-Reply. (2017) (2)
The Ups and Downs of Amyloid in Alzheimer’s (2021) (2)
Change in amyloid deposition is related to concurrent cognitive change in MCI (2011) (2)
COGNITION IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHIEMER’S DISEASE (2014) (2)
Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review (2022) (2)
Amyloid-Based Therapeutics: Findings Translated into Novel Treatments (2008) (2)
Impact of sex and APOE ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults (2022) (2)
A STEP FORWARD IN INTEGRATING HEALTHCARE AND VOICE-ENABLED TECHNOLOGY: CONCEPT DEMONSTRATION WITH DEPLOYMENT OF AUTOMATIC MEDICAL CODING MODEL AS AN AMAZON “ALEXA” SKILL (2018) (2)
AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid (2021) (1)
Alzheimer's Disease Cooperative Study Prevention Instrument Project Assessing Resource Use and Volunteer and Paid Work in Healthy Elders: A Longitudinal Study (2014) (1)
Predicting the course of Alzheimer’s progression (2019) (1)
Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force (2018) (1)
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease (2022) (1)
Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial (2022) (1)
Butyrylcholinesterase pharmacogenomics in mild cognitive impairment (2010) (1)
Brain volume changes with divalproex sodium in Alzheimer's disease (2010) (1)
COLLABORATION FOR ALZHEIMER’S PREVENTION (CAP): ADVANCING THE EVALUATION OF PRECLINICAL ALZHEIMER’S DISEASE TREATMENTS (2016) (1)
Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease (2012) (1)
Initial exploration of a brain age score based on validated computerized cognitive assessments in Japanese individuals (2020) (1)
Development of A b terminal end-specific antibodies and sensitive ELISA for A b variant (2004) (1)
Whole Blood Robotic Cholinesterase Assay for Organophosphate Exposure - Testing Soldiers, First Responders, and Civilians in the Field and Laboratory (2006) (1)
Age and APOE genotype influence rate of cognitive decline in non-demented elderly (2013) (1)
Cerebrospinal fluid biomarker outcomes in a trial of docosahexaenoic acid (DHA) for Alzheimer's disease (2010) (1)
COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS (2014) (1)
ADCS electronic data capture: Integrated image management (2013) (1)
Reducing noise in the ADAS-COG wordlist task (2009) (1)
Journal of Prevention of Alzheimer's Disease (JPAD): Building a "Fleet" Against Alzheimer's Disease. (2014) (1)
THE ASSOCIATION BETWEEN INSTRUMENTAL ACTIVITIES OF DAILY LIVING AND CORTICAL AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS SCREENING FOR THE A4 STUDY (2019) (1)
FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER’S DISEASE (2019) (1)
CSF biomarker and PIB-PET—derived beta-amyloid signature predicts Brain metabolism, grey matter and cognitive changes in non-demented subjects (2011) (1)
The Validity of Self-Reported Functional Decline Varies by Disease Severity (P04.205) (2012) (1)
REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING (2014) (1)
Injury and Disease Linkages Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative * (2014) (1)
Policy Forum 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (1)
RESVERATROL ACTIVATES THE CNS SIRTUIN1/MATRIX METTALOPROTEINASE-9 PATHWAY AND REGULATES NEUROINFLAMMATION IN ALZHEIMER’S DISEASE (2016) (1)
Leon Thal and the therapeutic age of Alzheimer’s disease (2008) (1)
Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease (2018) (1)
Is it time to use predictive models to boost power of Alzheimer’s disease clinical trials? A post‐hoc analysis of phase 3 solanezumab trials (2020) (1)
The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative (2021) (1)
P4-343: Omega 3 fatty acids and Alzheimer's disease: Trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease (2008) (1)
Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006 (2006) (1)
Disclosure of amyloid status in the a4 trial (2015) (1)
Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS (2020) (1)
Natural cubic splines for the analysis of Alzheimer's clinical trials. (2022) (1)
No cross-sectional influence of APOE ɛ4 dose on clinical tests in Alzheimer's disease (2009) (1)
P4-337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study (2008) (1)
double-blind pilot clinical trial Nicotine treatment of mild cognitive impairment : A 6-month (2011) (1)
Validating Alzheimer's pathological cascade by merging ADNI with PAQUID (2012) (1)
FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE-3 TRIAL OF VERUBECESTAT IN PRODROMAL AD (2019) (1)
TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK (2014) (1)
Callosal atrophy in mild cognitive impairment and Alzheimer's disease (2011) (1)
Predictors of progression in the ADNI-MCI cohort (2010) (1)
Self-reported versus informant-based cognitive complaints: Relation of E-Cog scores to imaging biomarkers and clinical status in ADNI-2 (2013) (1)
EFFECTS OF TRAUMATIC BRAIN INJURY AND POST-TRAUMATIC STRESS DISORDER ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING ADNI (2014) (1)
Alternatives to MMRM for preclinical Alzheimer’s clinical trials (2020) (1)
ASSESSING CLINICAL PROGRESSION FOR DEMENTIA PREVENTION TRIAL: RESULTS FROM THE HBA TRIAL (2014) (1)
SINGLE ENDPOINT FOR NEW DRUG APPROVALS FOR ALZHEIMER ’ S DISEASE (2017) (1)
Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative (2010) (1)
Designing Early (pre-dementia) Alzheimer's Disease Trials: Linear Mixed Models Versus Time To Conversion (2009) (1)
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease. (2023) (0)
Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
USING AN INTERNET REGISTRY TO SUPPLEMENT RECRUITMENT EFFORTS FOR CLINICAL RESEARCH (2016) (0)
ITEM-LEVEL COMPARISON OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX BY AMYLOID PET FROM THE A4 STUDY (2019) (0)
Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to Alzheimer's disease (2010) (0)
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab (2023) (0)
SAMPLE SIZES FOR 24-MONTH ALZHEIMER’S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS (2017) (0)
Abstract Sixteenth annual meeting of the society for clinical trialP44 Implementation of multicenter clinical trials: The Alzheimer's Disease Cooperative Study protocol implementation manual (1995) (0)
Cognitive, neuropsychiatric and imaging comparisons between early‐onset and late‐onset Alzheimer’s disease participants from LEADS and ADNI3 (2021) (0)
Developing outcome measures for therapeutic trials for dementia in aging individuals with Down Syndrome (2005) (0)
INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE (2014) (0)
Commentary on “Biomarkers in Alzheimer's disease drug development.” Can't live without ‘em (2011) (0)
Effect of list word presentation order on noise level in verbal memory tasks (2010) (0)
P4-265 BACE1 inhibition reduces Abeta production and alters APP processing in non-transgenic mice (2006) (0)
Tau positron emission tomography in preclinical Alzheimer's disease. (2022) (0)
ADCS EDC: DATA EXCHANGE AND PROCESSING PLATFORM (2014) (0)
PredictingReductionofCerebrospinalFluidβ-Amyloid42 inCognitivelyHealthyControls (2015) (0)
JAMA Neurology Peer Reviewers in 2016. (2017) (0)
ADCS EDC (2012) (0)
Clinical trials of anti-amyloid agents (2005) (0)
P4-297 Development of full-length mouse amyloid beta ELISA and determination of endogenous Abeta level in BACE1 knockout mice (2006) (0)
NSAIDs in the Treatment of Alzheimer's Disease (2004) (0)
Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer’s Disease Study (LEADS) sample: Results from the MRI core (2020) (0)
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease (2017) (0)
Quality of Life – 5 Dimensions ( EQ-5 D ) scale ( proxy version ) , 15 the Quality of Life in Alz (2014) (0)
Pharmacological Therapies for Alzheimer’s Disease (2014) (0)
The anti‐amyloid treatment in asymptomatic Alzheimer’s disease (A4) study: Report of screening and recruitment characteristics of the Melbourne composite site (2020) (0)
RARE VARIANT IN PLD3 IS ASSOCIATED WITH ALZHEIMER'S PATTERN OF NEURODEGENERATIVE CHANGES (2014) (0)
Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities (2015) (0)
P1-407 ADCS prevention instrument project: overview and initial results (2004) (0)
Collaborating in AD Research (2008) (0)
Docosahexaenoic Acid Supplementation and Alzheimer Disease—Reply (2011) (0)
Study partner factors on cognitive function index scores among participants screened for the A4 study (2020) (0)
RARE VARIANT IN PLD3 IS ASSOCIATED WITH ALZHEIMER'S PATTERN OF NEURODEGENERATIVE CHANGES (2014) (0)
P4-333 NAP reduces phosphorylated tau in AD transgenic mice (2006) (0)
Estimations of the prevalence of epilepsy in sub-Saharan Africa (2008) (0)
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease (2016) (0)
BRAIN AMYLOID BURDEN, SLEEP, AND CIRCADIAN REST/ACTIVITY RHYTHMS: SCREENING FINDINGS FROM A4 AND LEARN (2018) (0)
NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET (2014) (0)
We Have Turned the Corner (2022) (0)
ADVANCING CLINICAL AND BIOMARKER RESEARCH IN AD: THE LEAD STUDY (2019) (0)
Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (0)
JPAD Is Moving Fast. (2016) (0)
Medical evaluation of the elderly psychiatric patient. (1991) (0)
P2-389 EMPLOYING LYMPHOCYTE PROLIFERATIONAS A MEANS TO ASSESS CELL CYCLE DYSREGULATION IN COGNITIVELY IMPAIRED SUBJECTS: CLINICAL PERFORMANCE OF THE LYMPRO ASSAY (2014) (0)
Featured Article Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials (2016) (0)
PL-05-02: The evolution of Alzheimer's disease clinical trial design (2008) (0)
Individual patient data meta‐analysis assessing the adverse event profile of Alzheimer dementia randomized clinical trials (2021) (0)
Treatment of neurodegenerative diseases with nimesulide. (1997) (0)
High-Dose B Vitamin Supplements and Alzheimer Disease—Reply (2009) (0)
Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia (2015) (0)
Drs. Aisen and Davis Reply (1995) (0)
O2-05-08 A phase III study of the efficacy, safety and disease modification effect of tramiprosate in mild-to-moderate Alzheimer’s disease (2007) (0)
ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE (2014) (0)
P3‐013: Withdrawn (2015) (0)
Common gene networks underlying memory impairment: A comparison of pathway analysis methods in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (2012) (0)
THE LANGUAGE VARIANTS OF FRONTOTEMPORAL LOBAR DEGENERATION (2019) (0)
Occult aspiration of a nut in an elderly patient: a case report. (1988) (0)
Title Large-scale genomics unveil polygenic architecture of human cortical surface area Permalink (2015) (0)
Rate of decline in ADNI normal controls with evidence of amyloid burden (2010) (0)
OPTIMIZED PATHWAYS FOR EARLY DETECTION OF ALZHEIMER’S DISEASE WITH BLOOD-BASED BIOMARKERS (2019) (0)
Review Articles The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) (0)
INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS (2014) (0)
TD-P-016 DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER’S DISEASE (2018) (0)
Performance on ADAS-Cog items across ADCS trials (2012) (0)
Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks (2012) (0)
O4‐04‐06: Withdrawn (2015) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
Inflammatory Processes — Anti-Inflammatory Therapy (1997) (0)
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid (2022) (0)
Worldwide ADNI Update – July , 2012 (2013) (0)
Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia (2015) (0)
Georgetown University School of Medicine (2004) (0)
The effect of age and amyloid status on hippocampal atrophy rate in normal controls and people with mild cognitive impairment in the ADNI cohort (2013) (0)
Anticholinergic medication use in older adults is associated with memory and hippocampal volume (2015) (0)
FTS3-01-03 PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLYALZHEIMER’S DISEASE WITH LANABECESTAT FINAL EFFICACY, SAFETYAND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZH (2019) (0)
MEASURES OF COGNITION IN PRECLINICAL ALZHEIMER’S (2019) (0)
Adcs electronic data capture: Collaborative development and management of clinical trial databases (2013) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
Association of Subjective Cognitive Complaints and Objective Cognitive Impairment in Late Life Depression (2018) (0)
ADCS data sharing (2012) (0)
Ab immunotherapy results in down-regulation of microglial activation and potentially reduces the inflammation-mediated component of neurode- generation of AD. P1-345 CONSEQUENCES OF BETA-AMYLOID IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE ON NEURONS IN THE HUMAN CEREBRAL CORTEX (2013) (0)
DAMAGING EFFECT OF THE BUTYRYLCHOLINESTERASE K-VARIANT IN DONEPEZIL THERAPY OF MILD COGNITIVE IMPAIRMENT (2016) (0)
Erratum to: Effect of Tramiprosate in Patients with Mild-to-moderate Alzheimer’s disease: Exploratory Analyses of the MRI sub-group of the Alphase study (2010) (0)
Evaluation of the relationship between TTP488 plasma concentrations and changes in ADAS-cog relative to placebo (2013) (0)
AMYLOID RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN THE A4 SCREENING POPULATION (2019) (0)
Circulating hydroxy fatty acids in I (neutrophil aggregation/lipoxygenase/icosanoids/colchicine) (2016) (0)
IC-P3-165: 3D comparison of low, intermediate and advanced hippocampal atrophy in MCI (2008) (0)
ImpactoftheAlzheimer'sDiseaseNeuroimagingInitiative,2004to2014 (2015) (0)
Drug development in Alzheimer’s disease: the path to 2025 (2016) (0)
GERIATRIC DEPRESSION SCALE (GDS) ITEM-LEVEL ANALYSIS BY AMYLOID PET AND COGNITION: FINDINGS FROM THE ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER’S DISEASE (A4) STUDY SCREENING DATA (2019) (0)
Mail-In Cognitive Function Screening Instrument (2019) (0)
[Presence of plaque and gingivitis in pre-school children]. (1979) (0)
INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS (2014) (0)
SympoSia S 1-APECS TRIAL OF THE BACE 1 INHIBITOR VERUBECESTAT FOR PRODROMAL ALZHEIMER ’ S DISEASE (2018) (0)
receptors and the PI3K-Akt pathway in the case of galantamine and donepezil but not for rivastigmine. P4-296 AMYLOID- PEPTIDE REMNANTS IN AN-1792- IMMUNIZED ALZHEIMER’S DISEASE PATIENTS (2006) (0)
Inclusion criteria and cognitive responses to optimize trials in Alzheimer’s disease (2015) (0)
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease (2019) (0)
P1-093 ADCS prevention instrument project: mail-in cognitive function screening instrument (MCFSI) (2004) (0)
Extent and impact of missing ADAS-cog items in ADCS clinical trials (2011) (0)
The role of APOE genotype in early mild cognitive impairment (E-MCI): Preliminary results from ADNI-2 (2012) (0)
Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target (2015) (0)
TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK (2014) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) AND AMYLOID STATUS AMONG NORMAL OLDER ADULTS (2018) (0)
Bayesian Longitudinal Modeling on Placebo Data from Alzheimer’s Disease Clinical Studies (P1.010) (2014) (0)
Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease. (1993) (0)
Development and implementation of the National Alzheimer's Prevention Registry (2013) (0)
Prediction of longitudinal clinical outcomes of MCI population using Alzheimer’s AT[N] biomarker profiling: Can machine learning methods improve our predictions? (2020) (0)
DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER’S DISEASE (2018) (0)
Genetic associations with brain amyloidosis (2020) (0)
The placebo data analysis in Alzheimer's disease and mild cognitive impairment (MCI) clinical trials project: Overview of progress in trial data collection, and key findings from the pooled MCI trial datasets (2012) (0)
SAMPLE SIZES FOR 24-MONTH ALZHEIMER’S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS (2017) (0)
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (0)
DESIGN OF A PHASE-3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD (2018) (0)
CLASSIFICATION OF EMOTIONAL RESPONSES IN VIDEO AND AUDIO RECORDINGS USING A CONVOLUTIONAL NEURAL NETWORK (2018) (0)
Utilizing study and site performance metrics to improve efficiency of clinical trials: An initiative of the Alzheimer’s Clinical Trials Consortium (ACTC) (2021) (0)
PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS (2018) (0)
Antioxidants for Alzheimer disease-reply. (2013) (0)
DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER’S DISEASE (2018) (0)
Unsuccessful trials of therapies (2019) (0)
No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. (2009) (0)
ADCS EDC: INVESTIGATIONAL PRODUCT MANAGEMENT SYSTEM (2014) (0)
Featured Article The transitional association between b-amyloid pathology and regional brain atrophy (2015) (0)
ANTINUCLEAR ANTIBODIES IN MULTIPLE SCLEROSIS. AUTHOR'S REPLY (1995) (0)
Association of eye disease with increased diffusivity in the sagittal stratum (2015) (0)
MODELING LONG-TERM DISEASE PROGRESSION WITH COVARIATES (2014) (0)
The Aging Brain - Does Amyloid Matter? (2014) (0)
SELEGILINE (L‐DEPRENYL) IMPROVES BEHAVIOURAL SYMPTOMS IN ALZHEIMER'S DISEASE (AD) (1992) (0)
44% of CDR 0 persons, did not correlate with onset or progression of Alzheimer dementia, in contrast to the accurate prediction of future onset of AD dementia by informant reports of memory prob- (2019) (0)
BACE INHIBITOR VERUBECESTAT (MK-8931): BASELINE CHARACTERISTICS FOR PARTICIPANTS ENROLLED IN THE PHASE II/III EPOCH ALZHEIMER’S DISEASE TRIAL (2016) (0)
Factors that influence use of plasma beta-amyloid as a biomarker of Alzheimer's disease (2013) (0)
Emerging treatment strategies for alzheimer’s disease (2005) (0)
Informatics and Geriatric Psychiatry. (1996) (0)
Protective variant for rate of hippocampal volume loss identified by whole exome sequencing in APOE-ε3ε3 males with MCI (2013) (0)
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease (2017) (0)
Assessing Health Related Resource use in Normal Elders and Subjects With Mild Cognitive Impairment (2010) (0)
VERUBECESTAT-INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID-ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD-TO-MODERATE ALZHEIMER’S DISEASE PATIENTS (2019) (0)
REVISING THE ADMINISTRATION OF THE ADAS-COG (2014) (0)
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease (2016) (0)
Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities (2015) (0)
P1-367 COMPARISON OF IOFLUPANE-SPECT FINDINGSUSINGDATQUANT IN PATIENTS WITHALZHEIMER’S DISEASEDEMENTIA AND DEMENTIAWITH LEWY BODIES (2019) (0)
IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE (2018) (0)
33 – Anti-inflammatory and Antioxidant Therapies in Alzheimer's Disease (2001) (0)
Authors response to D. Umbricht letter to the editor referring Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer’s Disease, 2020 (2019) (0)
I. ADNI I, GO and II Part A: Leadership and Infrastructure Principal Investigator (2017) (0)
P4-387: Adding delayed recall to the Alzheimer's disease assessment scale–cognitive subscale (ADAS-cog): Sensitivity in a clinical trial for Alzheimer's disease and mild cognitive impairment (2008) (0)
P4-355 Optimal Aβ binding sites for sequestration therapy (2004) (0)
Association of eye disease with increased diffusivity in the sagittal stratum (2015) (0)
218. Anti-inflammatory drug studies in Alzheimer's disease (1996) (0)
Anticholinergic medication use in older adults is associated with memory and hippocampal volume (2015) (0)
P-198 Huperzine A as a treatment for Alzheimer’s disease (2007) (0)
Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P-tau versus 83 proteomic analytes (2012) (0)
Genome-wide analysis of genetic variants associated with depressive symptoms in older adults (2013) (0)
P2-400 The development of huperzine A as a treatment for Alzheimer’s disease (2006) (0)
THE RELATIVE EFFICIENCY OF TIME-TO-PROGRESSION AND CONTINUOUS MEASURES OF COGNITION IN PRECLINICAL ALZHEIMER'S (2019) (0)
Progress in Neurotherapeutics and Neuropsychopharmacology: Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease (2008) (0)
Alzheimer's disease patients with adult child study partners are underrepresented in clinical trials and may experience slower cognitive decline (2012) (0)
OLIGOMERIC Ab (MDS-OAb) FOR ALZHEIMER’S DISEASE: REAL-WORLD EXPERIENCE FROM THE PHILIPPINES (2019) (0)
EFFECTS OF AMYLOID STATUS AND AGE ON LONGITUDINAL REGIONAL BRAIN ATROPHY IN ELDERLY HEALTHY CONTROLS (2014) (0)
Traitement de pathologies neurodegeneratives par du nimesulide (1997) (0)
CROSS-VALIDATION OF OPTIMIZED COMPOSITES (2016) (0)
Title Alzheimer ' s disease progression by geographical region in a clinical trial setting Permalink (2015) (0)
Increased white matter MRI T1 hypointensity volume in young‐onset Alzheimer’s disease patients is not accounted for by age or cardiovascular risk factors (2020) (0)
PREVALENCE AND LONGITUDINAL CLINICAL OUTCOMES OF ALZHEIMER’S ATN BIOMARKER PROFILES: A LONGITUDINAL STUDY (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paul S. Aisen?

Paul S. Aisen is affiliated with the following schools:

Yale University
Albert Einstein College of Medicine
University of California, San Diego
University of Southern California
Georgetown University
Arizona State University

Paul S. Aisen's Academic­Influence.com Rankings

Why Is Paul S. Aisen Influential?

Paul S. Aisen's Published Works

Published Works

What Schools Are Affiliated With Paul S. Aisen?

Paul S. Aisen's AcademicInfluence.com Rankings